PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Bioequivalence Study Comparing Two Different Tafamidis Formulations
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2015-01-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26
- Registration Number
- NCT02217813
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
Food Effect Study for PF-06372865
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT02217787
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
A Study To Assess the Effects Of PF-04457845 On BOLD fMRI In Subjects With Post Traumatic Stress Disorder
- Conditions
- Post-Traumatic Stress Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2016-06-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT02216097
- Locations
- 🇺🇸
NYU CTSI Research Pharmacy (Drug Shipment Address), New York, New York, United States
🇺🇸Clinical and Translational Science Institute (CTSI), New York, New York, United States
🇺🇸NYU School of Medicine, New York, New York, United States
A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)
- Conditions
- Diabetic Neuropathy, Painful
- Interventions
- Drug: Matched placebo for PF-05089771 150 mg and pregabalin 300 mg
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 141
- Registration Number
- NCT02215252
- Locations
- 🇺🇸
Pulmonary Associates of Brandon (PAB), Brandon, Florida, United States
🇺🇸Beacon Clinical Research, LLC, Quincy, Massachusetts, United States
🇺🇸The Medical Research Network, LLC, New York, New York, United States
An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia B
- First Posted Date
- 2014-08-11
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT02213250
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
🇨🇳Hematology Department,Beijing Children's Hospital, Capital Medical University, Beijing, China
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
- Conditions
- Follicular Lymphoma
- Interventions
- Biological: PF-05280586Biological: MabThera®
- First Posted Date
- 2014-08-11
- Last Posted Date
- 2019-06-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 394
- Registration Number
- NCT02213263
- Locations
- 🇧🇪
PET/CT facility: Grand Hopital de Charleroi (GHdC) - site Notre-Dame, Charleroi, Belgium
🇧🇪Pharmacy Department, Centre Hospitalier De Jolimont - Lobbes, La Louviere (Haine-Saint Paul), Belgium
🇮🇹Unita di Ricerca Clinica, Monza, MB, Italy
A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Biological: PF-06293620Biological: Placebo
- First Posted Date
- 2014-08-07
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 84
- Registration Number
- NCT02211261
- Locations
- 🇺🇸
Avail Clinical Research, LLC, DeLand, Florida, United States
🇺🇸Profil Institute for Clinical Research, Inc., Chula Vista, California, United States
🇺🇸Profil Institute for Clinical Research, Incorporated, Chula Vista, California, United States
A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects
- First Posted Date
- 2014-08-05
- Last Posted Date
- 2015-03-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT02208284
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Evaluation of the Effect of Benzonatate on QT Intervals Following Single Dose Administration of Benzonatate to Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2014-08-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 68
- Registration Number
- NCT02207699
- Locations
- 🇺🇸
Pfizer Investigational Site, Overland Park, Kansas, United States
Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-08-01
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 39
- Registration Number
- NCT02206607
- Locations
- 🇺🇸
Clinical Trials of Texas, Inc., San Antonio, Texas, United States
🇺🇸High Point Clinical Trials Center, High Point, North Carolina, United States